Lixte Biotechnology cancels 500,000 options, awards equal RSUs vesting immediately to CEO, CFO, and directors

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

CEO Geordan Pursglove: 350,000 options cancelled, 350,000 RSUs awarded; CFO Peter Stazzone: 50,000 each.
Directors Holloway, Primus, Felix, Sawyer: each 25,000 options cancelled and RSUs awarded.
RSUs granted under 2020 Stock Incentive Plan and vested immediately on April 15, 2026.
Committee states swap provides better retention/incentive for officers and directors.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.